By Ben Reynolds
Bank of Nova Scotia (NYSE:BNS) is the third-largest Canadian bank ranked by market cap.
Bank of Nova Scotia’s market cap is $64 billion The Toronto-Dominion Bank’s market cap is $83 billion Royal Bank of Canada’s market cap is $94 billion
Bank of Nova Scotia’s financial metrics should immediately stand out for value-focused dividend investors. The company has a high dividend yield of 4.1% and a low price-to-earnings ratio of 12.3. This helps the company to rank highly using The 8 Rules of Dividend Investing.
Bank of Nova Scotia released its 3rd quarter results on August 30. This article covers those results in detail.
Bank of Nova Scotia operates in 4 segments:
Canadian Banking International Banking Global Banking & Markets Other
The Canadian Banking segment is the company’s largest. It generated $930 million in net profit in the company’s most recent quarter. The Canadian Banking segment provides Canada with retail, small business, commercial banking, and wealth management services. The segment has more than 10 million customers and 1,000 branches across Canada.
Top Low Price Stocks For 2018: Fiat Chrysler Automobiles N.V.(FCAM)
- [By WWW.THESTREET.COM]
The showstopper by far in the early going is Waymo’s self-driving minivan (pictured below) in partnership with Fiat Chrysler (FCAM) . Waymo’s ultimate mom-mobile, coming from a business that was spun-off from Google’s parent company Alphabet Inc. (GOOG) last month, is equipped with self-driving sensors and vision systems.
Top Low Price Stocks For 2018: Texas Roadhouse, Inc.(TXRH)
- [By Dan Caplinger]
Steakhouse chain Texas Roadhouse (NASDAQ:TXRH) has had to deal with an extremely difficult business environment for restaurant companies, and investors know all too well how tough times can hurt major players in the industry. Last quarter, Texas Roadhouse disappointed investors with sluggish results, and the company wanted to start 2017 on a better footing.
- [By Teresa Rivas]
Texas Roadhouse(TXRH) tumbled more than 12% on Wednesday as itsfourth-quarter earningsand revenue fell short of expectations.
The restaurant chain said it earned 29 cents a share on revenue of $484.7 million. Analysts were expecting earnings per share of 38 cents on revenue of $497.3 million.
Same-restaurant sales grew 1.2% at company restaurants and 2% at domestic franchises. For the first 55 days of the first quarter, Texas Roadhouse said that same-store sales rose 1.5%.
The company also raised its dividend 10.5% to 21 cents a share.
Some analysts urged investors to keep the faith in the stock.Barclay’s JeffreyBernsteinreiterated an Overweight rating and $47 price target on thestock:
We believe TXRH fundamentals remain best-in-class. That said, the near-term focus remains on directional comps. And not unlike the broader industry, TXRH comps eased significantly to close 2016. Such led to disappointing 4Q16 results from top to bottom. Importantly, while the brand ‘is not immune’ to industry comp headwinds, the relative outperformance to the category was maintained. Looking to 2017, key guidance metrics were reiterated. While questions remain on whether the recent easing of industry comps will persist, we remain comforted by TXRH’s relative outperformance and easing comps as we move through 2017.
Maxim’s Stephen Andersonreiterated a Buy rating, although he took his price target down $4, to $52:
In our view, TXRH is not immune to the broader slowdown in Casual Dining, but we believe the company will emerge stronger than peers in the next few quarters.TXRHs disappointing 4Q16 comp of +1.3% (blended) was pulled down by a rare negative comp month in December (-2.1%), marking the first time this occurred in almost four years. Comps were +3% or better in both October and November, and comps so far in 1Q17 are positive despite a stormy start to the quarter in
- [By Demitrios Kalogeropoulos]
As for individual stocks, Texas Roadhouse (NASDAQ:TXRH) and Garmin (NASDAQ:GRMN)made large moves following their quarterly earnings announcements.
Top Low Price Stocks For 2018: Mayne Pharma Group Limited (MAYNF)
- [By SEEKINGALPHA.COM]
We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ